Introduction
============

Extranodal natural killer/T-cell lymphoma (ENKTCL) is a highly aggressive type of lymphoma strongly associated with Epstein-Barr virus infection that has a poor clinical outcome, and the incidence of ENKTCL is higher in Asian and Latin American countries compared with Western countries ([@b1-ol-0-0-10719],[@b2-ol-0-0-10719]). Most studies on ENKTCL are therefore based on the populations of eastern Asia, and Central and South America countries, and relatively little information about this disease in people from Western countries is available. Neoplastic cells express cytoplasmic-CD3ε, CD56 and cytotoxic molecules. Most studies have reported a 5-year survival rate of \<50% ([@b3-ol-0-0-10719]--[@b7-ol-0-0-10719]). The Ann Arbor staging system, which was originally used in Hodgkin lymphoma, is useful to assess prognosis ([@b8-ol-0-0-10719]). Most ENKTCL cases comprise local lesions and \~80% cases involve stage IE and IIE ([@b7-ol-0-0-10719],[@b9-ol-0-0-10719],[@b10-ol-0-0-10719]). The treatment options and clinical characteristics of this disease have always been an important issue ([@b11-ol-0-0-10719]--[@b13-ol-0-0-10719]). Previously, anthracycline-containing chemotherapy regimens, including the cyclophosphamide, doxorubicin, vincristine and prednisolone regimen, were commonly used in advanced ENKTL treatment; however, they did not achieve satisfactory results ([@b9-ol-0-0-10719]). Currently, L-asparaginase-based regimens are the main treatment option ([@b1-ol-0-0-10719]). ENKTCL mainly originates from the upper aerodigestive tract (UADT), which usually involves the nasal cavity, hypopharynx, Waldeyer\'s ring, larynx and oral cavity ([@b14-ol-0-0-10719]--[@b16-ol-0-0-10719]). The involvement of extra-UADT sites is relatively rare in ENKTCL. Previous studies reported that UADT-ENKTCL and extra-UADT-ENKTCL have different clinical features and prognoses ([@b17-ol-0-0-10719]--[@b19-ol-0-0-10719]). The present study aimed therefore to investigate and analyze the characteristics and survival outcomes of patients from the United States (US) with stage IE and IIE primary UADT-ENKTCL of the nasal cavity by using the Surveillance, Epidemiology, and End Results (SEER) program database. In addition, by combining multiple independent factors, including age, stage, radiation and primary site, a nomogram based on patients overall survival (OS) was developed. This nomogram may be used to predict the OS and prognosis of patients with ENKTCL.

Materials and methods
=====================

### Data source

Data were obtained from the SEER database ([www.seer.cancer.gov](www.seer.cancer.gov)), which includes 18 registries and comprises data from \~28% of the US population. The White, Black, Hispanic, American Indian and Alaskan, Asian and Hawaiian/Pacific Islander populations represented \~25, 26, 38, 44 and 50% of the total population, respectively, in the 18 registries ([@b20-ol-0-0-10719]--[@b22-ol-0-0-10719]).

Cases based on the third edition of the International Classification of Disease for Oncology (ICD-O-3) were selected ([@b8-ol-0-0-10719]). In this study, patients with ENKTCL were identified using the ICD-O-3 code for histology (9719, ENKTCL). In particular, patients with stage IE and IIE UADT-ENKTCL were selected; however, patients with unknown or higher stage UADT-ENKTCL and with stage I and II non-UADT-ENKTCL were excluded ([Fig. 1](#f1-ol-0-0-10719){ref-type="fig"}). A total of 396 patients were eventually enrolled in the present study and were divided into training (n=280) and validation (n=116) cohorts.

### Statistical analysis

Data were collected from the SEER database using the SEER stat 8.3.5 software (<https://seer.cancer.gov/data/>). Statistical analyses were performed using the statistical software packages SPSS 21.0 (IBM Corp.) and R-project version 3.5.1 (<http://www.r-project.org/>) for Windows. OS curves were analyzed using the Kaplan-Meier method and the differences between groups were compared using the log-rank test. Univariate and multivariate analyses and calculation of hazard ratio (HR) were performed using the Cox regression model. A nomogram based on multivariate analysis by the rms package (<https://cran.r-project.org/web/packages/rms/index.html>) in Rand Harrell\'s C statistic was built and calibration curves were used to estimate the accuracy of the prediction model ([@b23-ol-0-0-10719],[@b24-ol-0-0-10719]). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Patient characteristics

A total of 396 patients with UADT-ENKTCL identified in the SEER database were included in the present study. In the entire study cohort, median follow-up time was \~18 months (range, 0--152 months). Median age at diagnosis was \~52 years (range, 8--93 years). There were 178 deaths among the 396 patients at 2--140 months, accounting for 44.9% of the cohort. The clinical characteristics of patients in the training and validation cohorts are listed in [Table I](#tI-ol-0-0-10719){ref-type="table"}.

### Univariate and multivariate analyses of OS in the training cohort

In the training cohort, the variables in univariate Cox regression analysis were included as follows: Sex, ethnicity, stage, primary site, radiation therapy, surgery and age. Among these variables, stage, primary site, radiation therapy and age were significantly correlated with OS (P\<0.05; [Table II](#tII-ol-0-0-10719){ref-type="table"}). The survival curves are presented in [Fig. 2](#f2-ol-0-0-10719){ref-type="fig"}. Due to the limited availability of chemotherapy data, this treatment variable was not included in the analysis. In the multivariate analyses, factors with P\<0.1, including age, stage, primary site, radiation therapy and stage primary site, which is defined as the interaction of two variables, were included for the Cox regression analysis. The results demonstrated that age, stage, primary site and radiation therapy were independently associated with unfavorable OS ([Table II](#tII-ol-0-0-10719){ref-type="table"}).

### Nomogram development and validation

A nomogram was established based on the results of multivariate analyses. Age, stage, primary site and radiation therapy were included in the nomogram. A weighted total score was calculated for each factor and was then used to calculate and estimate the 3-year OS and the probability for 5-year OS ([Fig. 3](#f3-ol-0-0-10719){ref-type="fig"}). Harrell\'s C statistic of the nomogram was calculated to be 0.717 in the training cohort and 0.737 in the validation cohort, which indicated that that the discriminatory capacity of the nomogram was relatively clear and accurate. In addition, the calibration curves revealed excellent consistency between predicted OS and actual OS ([Fig. 4](#f4-ol-0-0-10719){ref-type="fig"}).

### Further analysis of patients\' outcomes associated with treatment methods

A subgroup analysis was performed involving 264 patients receiving chemotherapy. The subgroup analysis results are presented in [Table III](#tIII-ol-0-0-10719){ref-type="table"}. Univariate analysis demonstrated that stage, primary site and radiation therapy were significant factors in the chemotherapy group. Variables with P\<0.1 on univariate analysis were included in multivariate analysis. Age, which is generally considered as a clinically important variable, was included in the Cox regression analysis. Stage and radiation therapy remained independent prognostic indicators. This result indicated that, based on chemotherapy, radiation therapy was beneficial for increasing OS.

Discussion
==========

Stage IE and IIE UADT-ENKTCL account for the largest proportion of ENKTCL cases and have unique clinical features, such as tumors usually infiltrating the nasopharynx or surrounding areas ([@b15-ol-0-0-10719]). Compared with other ENKTCL cases, stage IE and IIE UADT-ENKTCL cases usually exhibit lower lactate dehydrogenase levels and better performance status ([@b25-ol-0-0-10719]). In recent years, radiotherapy has been considered to be the most effective treatment ([@b25-ol-0-0-10719]). In the present study, a novel nomogram was built for this particular patient group based on the characteristics of the US population. This nomogram was validated in a validation cohort.

A nomogram is a simple and intuitive statistical tool used to calculate survival probability by incorporating relevant determinants of a disease. It may therefore be a useful tool for clinicians to make clinical decisions ([@b26-ol-0-0-10719],[@b27-ol-0-0-10719]). In particular, in the field of oncology, nomograms can serve in designing various prediction models for survival, recurrence and metastasis ([@b28-ol-0-0-10719]--[@b32-ol-0-0-10719]).

The present study demonstrated that age, primary site, radiation therapy and stage were independent prognostic factors for OS. Previous studies reported that age is an important prognostic factor for OS ([@b33-ol-0-0-10719],[@b34-ol-0-0-10719]). In order to further stratify the nomogram, two cut-off points for age (45 and 65 years) were determined. The results demonstrated that HR of OS increased with age; however, older patients had worsen survival, notably patients \>65 year old. The primary site was also an important prognostic variable for ENKTCL. It has been demonstrated that patients with extra-nasal UADT-ENKTCL are more likely to have worsen OS compared with those with ENKTCL ([@b25-ol-0-0-10719],[@b35-ol-0-0-10719],[@b36-ol-0-0-10719]). Data about chemotherapy treatment were divided into 'receiving chemotherapy' and 'No/Unknown' groups; however, due to the uncertainty of certain data, this information was unusable for univariate or multivariate analysis. Subsequently, the analysis focused on the efficacy of additional radiotherapy in patients who were receiving chemotherapy. Previous studies reported that initial treatment with radiation therapy and subsequent chemotherapy is superior to chemotherapy alone, and to chemotherapy followed by radiation ([@b4-ol-0-0-10719],[@b37-ol-0-0-10719]). The present study also confirmed that radiation therapy was still an independent prognostic factor in the chemotherapy subgroup, which was consistent with the results of previous studies ([@b38-ol-0-0-10719],[@b39-ol-0-0-10719]). Avilés *et al* ([@b38-ol-0-0-10719]) and You *et al* ([@b39-ol-0-0-10719]) reported that radiation therapy, as complementary treatment for chemotherapy or as palliative treatment following chemotherapy, is superior to chemotherapy alone. With regards to the stage, numerous studies have compared the prognoses of stage IE and IIE ENKTCL with that of stage IIIE and IVE ENKTCL ([@b35-ol-0-0-10719],[@b40-ol-0-0-10719],[@b41-ol-0-0-10719]), and these studies reported that stage IIIE and IVE ENKTCL have worse prognostic results. However, only a few studies compared the prognoses of stage IE ENKTCL with that of stage IIE ENKTCL, including the studies by Wang *et al* ([@b42-ol-0-0-10719]) and Dai *et al* ([@b43-ol-0-0-10719]), which revealed that patients with stage IE ENKTCL have a longer OS, which was consistent with the results of the present study. In addition, the analysis of the subgroup of the chemotherapy group revealed that stage remained an important prognostic variable. Notably, studies from Wang *et al* ([@b42-ol-0-0-10719]) and Dai *et al* ([@b43-ol-0-0-10719]) reported that in early-stage ENKTCL, B symptoms, including fever, weight loss and night sweats, are not associated with prognosis. The results from the present study were consistent with those from these previous studies ([@b41-ol-0-0-10719],[@b42-ol-0-0-10719]), and were also similar to those from studies on some early-stage lymphomas ([@b44-ol-0-0-10719],[@b45-ol-0-0-10719]).

The present study presented certain limitations. Firstly, data selection from the SEER database may potentially cause selection bias, since this is prevalent in all non-prospective, nonrandomized studies. Secondly, SEER database does not include clinically meaningful variables, including the expression levels of Ki-67, lactate dehydrogenase, β2-microglobulin and local tumor invasiveness. Although the sample size was large, the present study is a retrospective study and needs to be validated in a cohort study. Thirdly, since information about patient treatment in the SEER database was incomplete, the present study did not include information on specific modalities and doses of radiotherapy and chemotherapy.

In conclusion, the present study analyzed prognostic data of stage IE and IIE UADT-ENKTCL from the SEER database and developed a prognostic nomogram. This nomogram may predict the OS of patients with ENKTCL by using some clinically common variables. This nomogram may guide clinicians in better decision-making and have crucial clinical applications.
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###### 

Clinical characteristics of patients with extranodal natural killer/T-cell lymphoma in the training and validation cohorts.

  Variable                   Training cohort, n (%)   Validation cohort, n (%)   Total, n   P-value
  -------------------------- ------------------------ -------------------------- ---------- ---------
  Age, years                                                                                
    ≤45                      110 (39.3)               42 (36.2)                  152        0.751
    \>45 and ≤65             107 (38.2)               49 (42.2)                  156        
    \>65                     63 (22.5)                25 (21.6)                  88         
  Sex                                                                                       
    Male                     182 (65)                 81 (69.8)                  257        0.903
    Female                   98 (35)                  35 (30.2)                  139        
  Ethnicity                                                                                 
    White                    199 (72.1)               88 (75.9)                  287        0.367
    Other                    77 (27.9)                27 (24.1)                  104        
  Stage                                                                                     
    IE                       190 (67.9)               77 (66.4)                  267        0.775
    IIE                      90 (32.1)                39 (33.6)                  129        
  B symptoms                                                                                
    Yes                      62 (30)                  23 (27.6)                  85         0.939
    No                       145 (70)                 55 (72.4)                  200        
  Primary site                                                                              
    Nasal cavity and sinus   216 (77.1)               93 (80.2)                  309        0.520
    Other                    64 (22.9)                23 (19.8)                  87         
  Radiation                                                                                 
    Yes                      183 (66.3)               83 (71.6)                  266        0.508
    No                       93 (33.7)                33 (28.4)                  126        
  Surgery                                                                                   
    Yes                      201 (71.8)               87 (75)                    288        0.513
    No                       79 (28.2)                29 (25)                    108        
  Chemotherapy                                                                              
    Yes                                                                          264        
    No/unknown                                                                   132        

###### 

Univariate and multivariate analysis for overall survival of patients with extranodal natural killer/T-cell lymphoma.

                                    Univariate analysis    Multivariate analysis                          
  -------------------------- ------ ---------------------- ----------------------- ---------------------- ---------
  Age, years                                                                                              
    ≤45                      21.8                                                                         
    \>45 and ≤65             19.6   1.433 (0.957--2.146)                           1.253 (0.832--1.889)   
    \>65                     19.0   1.609 (1.017--2.547)   0.025                   1.823 (1.147--2.896)   0.044
  Sex                                                                                                     
    Male                     17.0                                                                         
    Female                   26.5   0.701 (0.483--1.018)   0.062                                          
  Ethnicity                                                                                               
    White                    19.1                                                                         
    Other                    22.1   0.923 (0.628--1.356)   0.682                                          
  Stage                                                                                                   
    IE                       23.2                                                                         
    IIE                      14.4   2.065(1.458--2.923)    \<0.001                 2.143 (1.498--3.066)   \<0.001
  B symptoms                                                                                              
    No                       19.3                                                                         
    Yes                      17.7   1.251 (0.797--1.962)   0.330                                          
  Primary site                                                                                            
    Nasal cavity and sinus   22.7                                                                         
    Other                    12.5   2.030 (1.395--2.955)   0.029                   1.686 (1.149--2.473)   0.008
  Radiation                                                                                               
    Yes                      24.6                                                                         
    No                       11.8   2.677 (1.888--3.795)   \<0.001                 2.752 (1.927--3.932)   \<0.001
  Surgery                                                                                                 
    Yes                      21.4                                                                         
    No                       17.7   0.730 (0.487--1.094)   0.127                                          

OS, overall survival; CI, confidence interval.

###### 

Univariate and multivariate subgroup analysis for overall survival of patients with extranodal natural killer/T-cell lymphoma that received chemotherapy.

                                     Univariate analysis    Multivariate analysis                          
  -------------------------- ------- ---------------------- ----------------------- ---------------------- ---------
  Age, years                                                                                               
    ≤45                      62.7                                                                          
    \>45 and ≤65             56.4    1.156 (0.776--1.722)                                                  
    \>65                     576.1   1.111 (0.599--2.061)   0.772                                          
  Sex                                                                                                      
    Male                     57.9                                                                          
    Female                   62.4    0.785 (0.528--1.168)   0.232                                          
  Race                                                                                                     
    White                    58                                                                            
    Other                    53.8    1.073 (0.709--1.622)   0.74                                           
  Stage                                                                                                    
    IE                       69                                                                            
    IIE                      41.9    2.250 (1.548--3.270)   \<0.001                 2.316 (1.590--3.374)   \<0.001
  B symptoms                                                                                               
    No                       63.8                                                                          
    Yes                      70.6    0.910 (0.529--1.568)   0.735                                          
  Primary site                                                                                             
    Nasal cavity and sinus   62.1                                                                          
    Other                    48      1.840 (1.19--2.845)    0.006                                          
  Radiation                                                                                                
    Yes                      67.5                                                                          
    No                       37.1    2.621 (1.787--3.842)   \<0.001                 2.700 (1.841--3.962)   \<0.001
  Surgery                                                                                                  
    Yes                      58.5                                                                          
    No                       61.7    0.934 (0.621--1.404)   0.741                                          

OS, overall survival; CI, confidence interval.
